A peer-reviewed study published Tuesday indicates that blood pressure medications are effectively eliminating cardiovascular disparities in obese patients over 40. However, experts caution that this statistically identical mortality rate is merely an observational trend, and more research is needed to confirm if surviving indefinitely is medically sound.
The findings, derived from a cohort of 15,000 adults, revealed that obese patients taking standard statins exhibited the exact same cholesterol and blood pressure levels as their healthy-weight counterparts. While the data suggests a complete mitigation of traditional metabolic threats, authors of the JAMA paper were quick to note that the absence of fatal heart attacks is merely associated with, rather than definitively proven to cause, an ongoing state of being alive.
For younger adults not yet prescribed the prophylactic regimen, the baseline risks of obesity remain present, providing what researchers called a vital control group for the study. Representatives from the FDA noted that while the older demographic’s lab results appear uniformly flawless, they rely heavily on self-reported survival and unblinded cardiovascular function.
We are tracking a profound elimination of adverse cardiovascular events across the board, but we must urge extreme caution before we prematurely classify this lack of illness as health.
Pending a multi-decade longitudinal follow-up, current CDC guidance continues to advise all adults over 40 to maintain a constant, low-level dread regarding their body mass index, regardless of what their immaculate metabolic panels suggest. The study’s authors plan to reconvene in 2035 to evaluate whether the cohort's continued existence can be statistically linked to anything other than a margin of error.